Navigation Links
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
Date:9/25/2007

HORSHAM, Pa., Sept. 25 /PRNewswire/ -- Findings from an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating ustekinumab (CNTO 1275) in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st meeting of the World Congress of Dermatology, which takes place from Sept. 30 to Oct. 5, 2007 in Buenos Aires, Argentina.

The presentation, entitled CNTO 1275 (anti-IL-12/23p40) Treatment of Psoriasis: Phase 3 Trial Results will take place on Wednesday, Oct. 3, 2007 from 11 a.m. to 1 p.m. local time (GMT +3:00; 10:00 a.m. to 12:00 p.m. EDT), Room A, La Rural Convention Center, Buenos Aires, Argentina.

These first reported findings will be the subject of a live press briefing and webcast, which will be broadcast from the World Congress of Dermatology on Wednesday, Oct. 3 at 2 p.m. EDT. Media and analysts are invited to register at http://www.CNTO1275WCD.com and listen live on Oct. 3 as investigators from the trial will review and discuss the data.

About Ustekinumab

Ustekinumab is a new, fully-human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis and is being investigated as an infrequently-administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in normalizing the immune system and that are also believed to play a role in immune-mediated inflammatory diseases.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies will market ustekinumab in all countries outside of the United States.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin ce
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...., Nov. 26 Children who...gnificantly increased risk of developing mental il... a Mayo Clinic study published this month in Pedi...emy of Pediatrics. , , The retrospective st...ith strabismus (misaligned eyes) and compared them...
(Date:11/26/2008)...to 406 Subjects , , FRANKLIN, Mass., Nov. 2...Bulletin Board: PLCSF) announced today that it has...g Administration (FDA) for its U.S. pivotal trial ...uard System(TM) and associated therapy in the pre... , The FDA also approved PLC,s request to exp...
(Date:11/25/2008)..., Nov. 25 Kleinert Kutz...ormed the fifth U.S. hand transplant on Messina, N...le,s Jewish Hospital Hand Care Center on Monday, N... noon and was completed shortly after 9 p.m. in a ....newscom.com/cgi-bin/prnh/20081125/DC48555-a ) , ...
(Date:11/25/2008)...ISCO, Calif., Nov. 25 Proteolix, I... novel therapeutics that target,protein degradati...ay,announced that data from two ongoing Phase 2 c... will be presented at the upcoming 50th Annual Mee... Carfilzomib is the first in a new class,of spec...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 1Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 1334 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 1Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment Naive Hepatitis C Patients Show a High Rate of Early Virologic R 561 9Pre Workout Stretching Wont Prevent Sore Muscles 4020 1Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 1Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 2Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 3Virginia G Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative 4018 4
(Date:12/1/2008)...alker Chooses Two Tampa Beneficiaries for Par and ...AMPA, Fla., Dec. 1 The ...rity of Tampa Bay, Inc. and the Judeo Christian He...he 2009 Par and Poker Celebrity Challenge for Char..., , "It is only appropriate that events like...
(Date:12/1/2008)...the sunlight-derived nutrient tied to increased ca...HealthDay News) -- A lack of vitamin D, which is ...elps boost the risk of heart attacks and strokes, ...of studies linking increased cardiovascular risk w...efe, director of preventive cardiology at the Mid ...
(Date:12/1/2008)..., Dec. 1, 2008 The Arthritis Foundation announces...or research in arthritis. The recipients, Dr. Gera...Physicians and Dr. Michel Nussenzweig of Rockefell...ed research advancements in the cure and control o...zed for his research in the development and functi...
(Date:12/1/2008)... Va., Dec. 1 The Food A...d Julia E. Bradsher, Ph.D., as its new CEO, replac..., , Dr. Bradsher brings to FAAN extensive kn...l allergic reaction. For the past six years, as Se...team and strategic planning for all Dey Pharmaceut...
Breaking Medicine News(10 mins):Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2Health News:Vitamin D Vital for the Heart 2Health News:Vitamin D Vital for the Heart 3Health News:FAAN Names New CEO 2
... more than 57,000 children found that greater the ...ng poor or having a single mother who is a high sc...g sick, immaterial of race or health insurance cov...ved for long that growing up in physically or ment...
... industry a panel comprising European experts reco...a be approved for sales// in the European Union. T...f. The action of the pill Acomplia (rimonabant) i...t obesity. People on the pill eat less because the...
...ce for Wales published, figures for rates of serio...g MRSA. This step is taken to assure// the public ...h officials to protect the public. John Wardell, ...tion after a hip replacement operation at Abergele...
...to be a common problem with the Middle-aged and ol.... But now, Dr. Najah S. Musacchio, a fellow at Chi...p further in finding out if this problem could hav...er and understand, Musacchio and fellow researcher...
Other Medicine News:Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 2Health News:A New Study Shows Social Well Being Plays An Important Part In Childs Health 3
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL.
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid.
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
Medicine Products: